Asset Details
Do you wish to reserve the book?
Inhibition of Tumor Angiogenesis by Tumstatin : Insights into Signaling Mechanisms and Implications in Cancer Regression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inhibition of Tumor Angiogenesis by Tumstatin : Insights into Signaling Mechanisms and Implications in Cancer Regression
Do you wish to request the book?
Inhibition of Tumor Angiogenesis by Tumstatin : Insights into Signaling Mechanisms and Implications in Cancer Regression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inhibition of Tumor Angiogenesis by Tumstatin : Insights into Signaling Mechanisms and Implications in Cancer Regression
2008
Overview
Growing tumors develop additional new blood vessels to meet the demand for adequate nutrients and oxygen, a process called angiogenesis. Cancer is a highly complex disease promoted by excess angiogenesis; interfering with this process poses for an attractive approach for controlling tumor growth. This hypothesis led to the identification of endogenous angiogenesis inhibitors generated from type IV collagen, a major component of vascular basement membrane (VBM). Type IV collagen and the angiogenesis inhibitors derived from it are involved in complex roles, than just the molecular construction of basement membranes. Protease degradation of collagens in VBM occurs in various physiological and pathological conditions and produces several peptides. Some of these peptides are occupied in the regulation of functions conflicting from those of their original integral molecules. Tumstatin (alpha3(IV)NC1), a proteolytic C-terminal non-collagenous (NC1) domain from type IV collagen alpha3 chain has been highlighted recently because of its potential role in anti-angiogenesis, however its biological actions are not limited to these processes. alpha3(IV)NC1 inhibits proliferation by promoting endothelial cell apoptosis and suppresses diverse tumor angiogenesis, thus making it a potential candidate for future cancer therapy. The present review surveys the physiological functions of type IV collagen and discovery of alpha3(IV)NC1 as an antiangiogenic protein with a comprehensive overview of the knowledge gained by us towards understanding its signaling mechanisms.
Publisher
Springer,Springer Nature B.V
Subject
/ Angiogenesis Inhibitors - pharmacology
/ Animals
/ Autoantigens - therapeutic use
/ Biological and medical sciences
/ Cancer
/ Collagen
/ Collagen Type IV - pharmacology
/ Collagen Type IV - physiology
/ Collagen Type IV - therapeutic use
/ Humans
/ Integrin alpha3beta1 - physiology
/ Integrin alphaVbeta3 - physiology
/ Neovascularization, Pathologic - prevention & control
/ Peptides
/ Pharmaceutical technology. Pharmaceutical industry
/ Pharmacology. Drug treatments
/ Signal Transduction - physiology
/ Tumors
